Combination of | |
---|---|
Vonoprazan | Potassium-competitive acid blocker |
Amoxicillin | Beta-lactam antibiotic |
Clinical data | |
Trade names | Voquezna Dual Pak |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic.[1] It is taken by mouth.[1]
The co-packaged medication was approved for medical use in the United States in May 2022.[1][2][3][4]